Australia: High Court of Australia confirms patentability of methods of medical treatment


Consideration of what constitutes patentable subject matter has been a recurring theme in both Australian and U.S. Courts this year. In Australia, the Federal Court has considered the patentability of genetic/biological material1 as well as software and business methods2, while in the U.S., the Supreme Court held that isolated naturally occurring DNA sequences were not patent eligible3. The U.S. District Court also considered the patentability of diagnostic assays utilizing "principles of nature"4.

Judicial review of patentable subject matter in Australia continued on 4 December 2013 when the High Court of Australia confirmed by a 4 to 1 majority decision that methods of medical treatment of human beings, specifically the administration of therapeutic drugs, represent patent eligible subject matter.

Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50 (4 December 2013)


Australian Patent No 670491 (the Patent), owned by Sanofi-Aventis Deutschland GmbH, is directed to a method of using the known compound Leflunomide for the treatment of skin disorders and includes a single claim:

"A method of preventing or treating a skin disorder, wherein the skin disorder is psoriasis, which comprises administering to a recipient an effective amount of a pharmaceutical composition containing as an active ingredient a compound of the formula I or II".

A compound of the formula I is Leflunomide.

Apotex obtained registration of generic versions of Leflunomide (Apo-Leflunomide) with the intention to supply the pharmaceutical products as treatments for psoriatic arthritis and rheumatoid arthritis.

Sanofi-Aventis initiated proceedings against Apotex in the Federal Court of Australia alleging that Apotex's proposed supply of Apo-Leflunomide products for the treatment of psoriatic arthritis would infringe their patent.

Apotex cross-claimed for revocation of the Patent on a variety of grounds, none of which succeeded. Apotex appealed to the Full Court of the Federal Court. However, that appeal was dismissed.

On 14 December 2012, the High Court granted special leave to Apotex to appeal from the judgment of the Full Court in relation to the validity of the Patent. The single ground upon which special leave was granted was that the Full Court erred in finding that the claim defined a "manner of manufacture" within the meaning of s 18(1)(a) of the Patents Act 1990. Specifically, the question raised by Apotex was whether a method of medical treatment of human beings is capable of being a patentable invention.

The patentability of methods of medical treatment

Under Australian law, for an invention to be considered patent eligible subject matter it must satisfy the criteria of a "manner of manufacture within the meaning of section 6 of the Statute of Monopolies". This patentability threshold was considered in the landmark High Court decision of National Research Development Corp v Commissioner of Patents ("NRDC").

According to NRDC, if a process which does not produce a new substance but nevertheless results in "a new and useful effect" so that the new result is "an artificially created state of affairs" providing economic utility, it may be considered patent eligible.

However, the NRDC decision suggested in obiter that "processes for treating the human body may well lie outside the concept of a 'manner of manufacture' because the whole subject is conceived as essentially non-economic". Thus, Apotex argued that methods of medical treatment of humans are "essentially non-economic".

The majority of Justices rejected this argument. In particular, Crennan and Kiefel JJ, detailed seven reasons as to why the Apotex argument failed. The most "crucial" of these reasons stated that the subject matter of a claim for a new product suitable for therapeutic use, (a product claim) and the subject matter of a claim for an unknown method of treatment using a (known) product having prior therapeutic uses (a method claim), cannot be distinguished in terms of economics or ethics.

Gageler J and French CJ concurred with the findings of Crennan and Kiefel JJ. Notably, Chief Justice French distilled the majority decision by stating "the exclusion from patentability of methods of medical treatment represents an anomaly for which no clear and consistent foundation has been enunciated".

In his lone dissenting judgment, Justice Hayne considered that although methods of medical treatment might have economic consequences for an individual, the result of a method of medical treatment "goes beyond the ambit of a 'manner of manufacture'".


In relation to the infringement issue, the question before the High Court was whether the supply of Apo-Leflunomide would constitute an infringement of an indirect or contributory nature.

The two relevant arms of the contributory infringement section of the Patents Act 1990 that the High Court considered included:

  1. whether Apotex had "reason to believe" that medical practitioners would use Apo-Leflunomide for the claimed purpose, namely the prevention and treatment of psoriasis; and
  2. whether there was any inducement included with the instructions which would result in Apo-Leflunomide being used for the claimed purpose.

Regarding, point (1) it was stated at paragraph [304] of the judgment, "it was not shown, nor could it be inferred, that Apotex had reason to believe that the unpatented pharmaceutical substance, which it proposes to supply, would be used by recipients in accordance with the patented method, contrary to the indications in Apotex's approved product information document."

In relation to point (2), Apotex's approved product information states that Apo-Leflunomide is indicated for the treatment of active rheumatoid arthritis or active psoriatic arthritis. Apo-Leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease.

On the basis of the above, the proposed supply of Apo-Leflunomide was found not be an infringement the Patent.


This decision is significant because it provides certainty in relation to the patentability of methods of medical treatment of humans, in particular methods involving the administration of therapeutic drugs.

The decision also provides guidance regarding contributory infringement of method of treatment claims by the supply of pharmaceutical compounds. The findings of the High Court suggest that contributory infringement may be avoided by registering pharmaceutical products for indications that are distinct to those defined in a method of treatment claim.


1Cancer Voices Australia v Myriad Genetics Inc.

2Research Affiliates LLC v Commissioner of Patents

3Association for Molecular Pathology v. Myriad Genetics Inc.

4Ariosa Diagnostics, Inc. v. Sequenom, Inc.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Shelston IP has been awarded the MIP Global Award for Australian IP Firm of the Year 2013.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Grant Shoebridge
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.